Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries.
A retrospective analysis was conducted to examine factors affecting early mortality after myeloablative, single-unit cord blood transplantation (CBT) for hematological malignancies in adolescents and adults. Data were collected from the three main CBT registries pooling 514 records of unrelated, single, unmanipulated, first myeloablative allogeneic CBTs conducted in North America or Europe from 1995 to 2005, with an HLA match ≥ 4/6 loci, in patients aged 12-55. Overall 100-day, 180-day and 1-year survival (Kaplan-Meier method) were 56, 46 and 37%, respectively, with no significant heterogeneity across registries. Multivariate analysis showed cell dose < 2.5 × 10⁷/kg (odds ratio (OR) 2.76, P < 0.0001), older age (P = 0.002), advanced disease (P = 0.02), positive CMV sero-status (OR 1.37 P = 0.11), female gender (OR 1.43, P = 0.07) and limited CBT center experience (< 10 records contributed, OR 2.08, P = 0.0003) to be associated with higher 100-day mortality. A multivariate model predictive of 1-year mortality included similar prognostic factors except female gender. Transplant year did not appear as a significant independent predictor. This is the first analysis to pool records from three major CBT registries in the United States and Europe. In spite of some differences in practice patterns, survival was remarkably homogeneous. The resulting model may contribute to better understanding factors affecting CBT outcomes.
Cohen
Y C
YC
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilnson Hospital, Petach Tikva, Israel. yaelc@vbl.co.il
Scaradavou
A
A
Stevens
C E
CE
Rubinstein
P
P
Gluckman
E
E
Rocha
V
V
Horowitz
M M
MM
Eapen
M
M
Nagler
A
A
Shpall
E J
EJ
Laughlin
M J
MJ
Daniely
Y
Y
Pacheco
D
D
Barishev
R
R
Olmer
L
L
Freedman
L S
LS
D000293:Adolescent; D000328:Adult; D000375:Aging; D002648:Child; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods / Q000401:mortality*; D003586:Cytomegalovirus Infections / Q000150:complications; D005060:Europe; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D009367:Neoplasm Staging; D009656:North America; D011379:Prognosis; D012042:Registries; D015203:Reproducibility of Results; D012189:Retrospective Studies; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000009:adverse effects; D055815:Young Adult
D019653:Myeloablative Agonists